A post hoc analysis of a 32-week randomised trial examined how semaglutide, empagliflozin and their combination altered renal diffusion-weighted MRI and total kidney volume in type 2 diabetes. PICO summary and expert commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
A small mechanistic randomized trial found once-daily oral semaglutide 50 mg cut ad libitum energy intake by 39.2 percentage points versus placebo and reduced body weight, with no change in gastric emptying. PICO summary and expert commentary.
PIONEER 12 was a 26-week double-blind Phase IIIa trial showing all three doses of once-daily oral semaglutide lowered HbA1c and body weight more than sitagliptin 100 mg in a predominantly Chinese type 2 diabetes population. PICO summary and expert commentary.
Phase IIIa double-blind trial of oral semaglutide monotherapy vs placebo in a predominantly Chinese type 2 diabetes population, with HbA1c and body-weight findings. PICO summary and expert commentary.
STEP 10 phase 3 RCT: once-weekly semaglutide 2.4 mg cut bodyweight by 13.9% and drove reversion to normoglycaemia in adults with obesity and prediabetes. PICO summary and expert commentary.
Pooled subgroup analysis of STEP-HFpEF and STEP-HFpEF-DM finds once-weekly semaglutide 2.4 mg improves symptoms and weight across diuretic strata and cuts loop diuretic dose in obesity-related HFpEF. PICO summary and expert commentary.
A post-hoc pooled analysis of four randomised trials found once-weekly semaglutide lowered the composite of cardiovascular death or worsening heart failure events in patients with HFpEF, with no significant effect on cardiovascular death alone. PICO summary and expert commentary.
A prespecified FLOW analysis found once-weekly semaglutide 1 mg lowered the risk of heart failure events or cardiovascular death in adults with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
Secondary analysis of the SELECT trial finds semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes, with much of the non-cardiovascular benefit driven by fewer infectious and COVID-19-related deaths. PICO summary and expert commentary.
A prespecified pooled secondary analysis of the STEP-HFpEF trials found semaglutide improved symptoms, weight, and exercise capacity consistently across baseline C-reactive protein strata and lowered CRP regardless of weight loss. PICO summary and expert commentary.